NL-OMON28176
Not yet recruiting
Not Applicable
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
Conditionspre-clinical RA
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- pre-clinical RA
- Sponsor
- Academic Medical Center/University of Amsterdam, Amsterdam
- Enrollment
- 90
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with pre\-clinical RA, defined by the presence of arthralgia and at least one of the following features:
- •1\. IgM\-rheumatoid factor (IgM\-RF) of \> 12\.5 IU/ml;
Exclusion Criteria
- •1\. Clinically evident arthritis;
- •2\. History of arthritis;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.EUCTR2009-010955-29-NLDivision of Clinically Immunology and Rheumatology, AMC
Completed
Not Applicable
Primary prevention of rheumatoid arthritisRheumatoid arthritisMusculoskeletal DiseasesISRCTN73232918Jan van Breemen Instituut (Netherlands)80
Recruiting
Not Applicable
Primary prevention of rheumatoid arthritis.NL-OMON26301Prof.dr. B.A.C. DijkmansVUMC/Jan van Breemen Instituut80
Completed
Not Applicable
Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study)Rheumatoid arthritisJPRN-UMIN000001798Team RA, Rheumatosurgery, Osaka City University Medical School100
Unknown
Phase 4
Remission Induction in Very Early Rheumatoid ArthritisRheumatoid ArthritisNCT00523692University Hospital Birmingham20